Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07511309

FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial

Fractional Flow Reserve-Guided Revascularization in Atherosclerotic Renal Artery Stenosis: A Randomized Controlled Trial

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
300 (estimated)
Sponsor
Chinese Academy of Medical Sciences, Fuwai Hospital · Academic / Other
Sex
All
Age
40 Years – 80 Years
Healthy volunteers
Not accepted

Summary

For patients with atherosclerotic renal artery stenosis, the results of randomized controlled trials published in recent years have failed to demonstrate that renal artery stenting is superior to optimal medical therapy. However, these studies still have limitations. Fractional flow reserve (FFR) has been extensively studied in coronary artery disease, and it has been established that FFR-guided revascularization is superior to both angiography-guided percutaneous coronary intervention and medical therapy alone. Whether FFR can guide interventional treatment in patients with renal artery stenosis and hypertension is currently a hot topic in the field of renal artery stenosis research. Eligible patients meeting the inclusion criteria were enrolled. Pharmacologically induced FFR values were measured as the baseline. Patients with FFR ≥ 0.8 were randomly assigned to either the medical therapy group or the stenting group, while patients with FFR \< 0.8 underwent stent implantation. Changes in eGFR, 24-hour systolic blood pressure, and 24-hour diastolic blood pressure from baseline to 12 months were compared among the groups.

Conditions

Interventions

TypeNameDescription
DEVICERandomized to stentingPatients with pharmacologically induced renal FFR ≥ 0.80 will be randomly assigned to receive either stent implantation.
DEVICEstent implantationPatients with pharmacologically induced renal FFR \< 0.80 will receive stent implantatio.
DRUGRandomized to optimal medical therapy (OMT)Patients with pharmacologically induced renal FFR ≥ 0.80 will be randomly assigned to optimal medical therapy.

Timeline

Start date
2026-03-31
Primary completion
2027-05-31
Completion
2028-03-31
First posted
2026-04-06
Last updated
2026-04-06

Locations

20 sites across 1 country: China

Source: ClinicalTrials.gov record NCT07511309. Inclusion in this directory is not an endorsement.